<DOC>
	<DOCNO>NCT00001107</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness 2 treatment prevent invasive fungal infection ( IFI ) , infection cause yeast mold common patient weak immune system transplant patient . AmBisome , new treatment , compare fluconazole , traditional treatment fungal infection cause yeast Candida . Treatment give liver transplant patient find high risk IFI . Liver transplant patient low risk IFI monitor receive study medication . IFIs find mainly high risk group liver transplant patient , common low risk . If IFI preventive therapy focus high risk group , may lesser chance Candida become resistant ( able grow despite presence drug use kill ) . Treating high risk group also save money .</brief_summary>
	<brief_title>Comparison Two Treatments Prevent Invasive Fungal Infections Patients Who Have Received Liver Transplants</brief_title>
	<detailed_description>If high risk group assign randomly ( like toss coin ) receive either AmBisome fluconazole . If low risk group , receive treatment . Both group monitor IFIs . The study last 100 day follow liver transplant .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<criteria>You may eligible study : Have liver transplant within 5 day enrollment agree receive tacrolimus . You eligible study : Are HIVpositive . Have history invasive fungal infection . Have receive antifungal agent within 14 day prior liver transplant . Are allergic azoles , amphotericin B , tacrolimus .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
</DOC>